CorMedix Inc. is a specialty pharmaceutical company that develops and seeks to commercialize products for the treatment of cardiac, renal and infectious diseases. Specifically, our goal is to treat human disease by reducing commonly associated renal, cardiovascular, metabolic and infectious complications. Our therapeutic candidates may be small molecules, biologics, chemical entities, devices and/or diagnostics (molecular/lab tests) that enable targeted therapy in these areas.
CorMedix has received CE Mark approval for Neutrolin®, a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients. Our goal is to provide risk mitigation solutions for central venous catheters (CVCs) in a variety of important indications. Approval of Neutrolin® by FDA for commercial distribution in the U.S. is also being pursued.
Listen to what a key opinion leader has to say.
Click here to listen to a key opinion leader commenting on catheter related bloodstream infections, how they affect the dialysis patient population and current treatments available:
Michael Allon, MD, University of Alabama Birmingham, Birmingham Alabama